DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations
- None.
- The workforce reduction of approximately 30 employees, or approximately 15 percent of DermTech’s workforce, may impact the company's morale and productivity in the short term.
Insights
The announcement by DermTech regarding its restructuring actions and the expected reduction in operating expenses by approximately $40 million compared to the previous fiscal year is a significant development for the company and its investors. The actions, which include a workforce reduction of 15 percent, are aimed at prioritizing revenue growth and streamlining operations. This is a common strategy for companies seeking to improve their financial health, particularly when facing challenges in scaling their business or market adoption of their products.
From a financial perspective, the anticipated one-time restructuring charge of $1.3 million in the first quarter of 2024 is relatively small compared to the overall expected savings, suggesting a strategic move to strengthen the company's balance sheet. Investors and stakeholders will be interested in how these cost reductions translate into improved profitability and whether the focus on reimbursed tests will drive sufficient revenue growth to offset the costs of restructuring.
It is also important to consider the potential risks of such restructuring, which may include a loss of talent and a possible decrease in employee morale. However, if the company successfully reallocates resources towards high ROI opportunities, as stated by the CEO, the long-term benefits could include a more sustainable business model and enhanced shareholder value.
Restructuring within DermTech, especially in the precision dermatology space, reflects the company's response to the competitive healthcare market dynamics. The emphasis on growing the DermTech Melanoma Test (DMT) billable samples and expanding payer coverage is a strategic move to capture a larger market share in the non-invasive skin genomics technology sector.
By focusing on reimbursed tests, DermTech is likely aiming to align with insurance providers and healthcare payers, which is a critical factor in the adoption of new medical technologies. The success of such a strategy hinges on the company's ability to demonstrate the clinical and cost-effectiveness of their melanoma test to payers, which can be a complex and time-consuming process.
Given the company's focus on a lean organization, it will be crucial to monitor how the reduced workforce impacts its ability to innovate and maintain a competitive edge. The company's ability to adapt and refine commercial tactics in response to market feedback will be a key indicator of its potential to sustain revenue growth in the long term.
The DermTech Melanoma Test (DMT) represents a significant advancement in the field of precision dermatology, offering a non-invasive method for evaluating melanoma risk. DermTech's restructuring efforts to prioritize the growth of DMT billable samples indicates a strategic focus on this potentially life-saving technology.
In the context of medical research and clinical adoption, the effectiveness and accuracy of the DMT will be under scrutiny. It is essential for DermTech to continue investing in research and development to ensure that the DMT maintains high sensitivity and specificity standards, as these factors are critical for payer coverage decisions and widespread clinical use.
Furthermore, the company's decision to focus on reimbursed tests suggests an understanding of the importance of economic barriers in the healthcare industry. By seeking to expand payer coverage, DermTech is addressing a key hurdle in the patient access to innovative diagnostic tools. The long-term impact of these restructuring actions on the company's research capabilities and its ability to keep up with the evolving landscape of dermatological diagnostics will be important to assess.
- Ongoing emphasis on growing revenue for the DermTech Melanoma Test (DMT)
- Approximately
The Company has continued to rigorously evaluate its growth opportunities and operations, while dedicating substantially all of its resources to growing reimbursed DermTech Melanoma Test (DMT) billable samples and expanding payer coverage. These additional restructuring actions will primarily affect operations, but impact the entire organization, and will result in a workforce reduction of approximately 30 employees, or approximately 15 percent of DermTech’s workforce. The Company expects to achieve approximately
“As we wrapped up last year, we recommitted to rigorous capital allocation in support of revenue growth and finding additional operating efficiencies in 2024,” said Bret Christensen, CEO, DermTech. “Growing revenue remains our primary objective and we began to see meaningful improvement in many of our top-line and operating metrics during the third quarter of 2023. Our realigned commercial tactics and focus on reimbursed tests has yielded improvement in nearly all of our key performance indicators. We must continue to refine our approach as we learn more and be determined to achieve these goals with a lean organization and by aligning behind only the highest ROI opportunities.”
Christensen continued, “We recognize today’s additional restructuring actions will be difficult for our colleagues and their families. I’m extremely thankful for their commitment as we worked tirelessly to enhance the standard of care for evaluating melanoma.”
About DermTech
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics technology. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected using its Smart StickersTM. DermTech develops and markets products that facilitate the assessment of melanoma. For additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “runway,” "outlook," “anticipate,” “intend,” “plan,” “strive," “may,” “will,” “sustain,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products; expectations regarding DermTech’s potential growth, scale, patient reach, financial outlook, including its cash runway and future financial performance DermTech’s ability to increase its test volume, revenue and the proportion of reimbursed billable tests and control or reduce cost, expenses and cash burn; and expectations regarding agreements with or reimbursement or cash collection patterns from government payers (including Medicare) or commercial payers and related billing practices or number of covered lives. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by government payers (including Medicare) and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees and maintain or improve its operating efficiency and reduce operating expenses; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240131945520/en/
Steve Kunszabo
DermTech
(858) 291-1647
steve.kunszabo@dermtech.com
Source: DermTech, Inc.
FAQ
What is the ticker symbol for DermTech, Inc.?
What are the expected total operating expense reductions compared to fiscal 2022?
How many employees will be affected by the workforce reduction?
